Genentech Appeals To FDA's "Regulatory Flexibility"
This article was originally published in The Pink Sheet Daily
Executive Summary
The summary of the evidence Genentech will present at the June hearing on Avastin's breast cancer approval shows its case will focus on its proactive efforts to conduct a new confirmatory trial, but it also emphasizes the agency's options in applying its regulatory authority.
You may also be interested in...
US FDA Still Hasn’t Decided Who Will Be Final Arbiter On Approval Status For Covis’ Makena
With two weeks to go before hearing on whether the preterm birth prevention drug can stay on the market or be withdrawn, the lack of clarity on who will make the ultimate decision may stem from the lengthy duration of the dispute and multiple transitions within FDA’s senior leadership.
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
FDA Commissioner Margaret Hamburg faces a decision on the future of Avastin’s (bevacizumab) first-line metastatic breast cancer claim that may not be so cut and dried as the Oncologic Drugs Advisory Committee’s unanimous vote favoring the indication’s withdrawal suggests.
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
FDA Commissioner Margaret Hamburg faces a decision on the future of Avastin’s (bevacizumab) first-line metastatic breast cancer claim that may not be so cut and dried as the Oncologic Drugs Advisory Committee’s unanimous vote favoring the indication’s withdrawal suggests.